Monica Cacho

Monica Cacho

Auto-generated profile, based on publicly available information

Monica Cacho

Global Health R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
DBDelia Blanco
Delia Blanco
EPEsther Perez-Herran
Esther Perez-Herran
MCMónica Cacho
Mónica Cacho
LBLluis Ballell
Lluis Ballell
JCJulia Castro
Julia Castro
DBDavid Barros
David Barros
One way to speed up the TB drug discovery process is to search for antitubercular activity among compound series that already possess some of the key properties needed in anti-infective drug discovery, such as whole-cell activity and oral absorption. Here, we present MGIs, a new series of Mycobacterium tuberculosis gyrase inhibitors, which stem from the long-term efforts GSK has dedicated to the discovery and development of novel bacterial topoisomerase inhibitors (NBTIs). The compounds identified were found to be devoid of fluoroquinolone (FQ) cross-resistance and seem to operate through a mechanism similar to that of the previously described NBTI GSK antibacterial drug candidate. The remarkable in vitro and in vivo antitubercular profiles showed by the hits has prompted us to further advance the MGI project to full lead optimization.

10 January 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJennifer A. Borthwick
Jennifer A. Borthwick
CACarlos Alemparte
Carlos Alemparte
IWIan Wall
Ian Wall
BWBenjamin C. Whitehurst
Benjamin C. Whitehurst
AAArgyrides Argyrou
Argyrides Argyrou
RYRobert J. Young
Robert J. Young

28 April 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
OBOlga B Balabon
Olga B Balabon
EPEleni Pitta
Eleni Pitta
MRMaciej K. Rogacki
Maciej K. Rogacki
EMEugenia Meiler
Eugenia Meiler
RCRuth Casanueva
Ruth Casanueva
PVPieter Van Der Veken
Pieter Van Der Veken

22 February 2022 in ACS Infectious Diseases
Verified
Journal Article
Open access
BGBen Gold
Ben Gold
JZJun Zhang
Jun Zhang
LQLandys Lopez Quezada
Landys Lopez Quezada
JRJulia Roberts
Julia Roberts
YLYan Ling
Yan Ling
RBRobert H. Bates
Robert H. Bates
Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19. Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill Mycobacterium tuberculosis (Mtb). In the TB Drug Accelerator (TBDA), a consortium organized by the Bill & Melinda Gates Foundation, individual pharmaceutical companies collaborate with academic screening laboratories. We developed a higher order consortium within the TBDA in which four pharmaceutical companies (GlaxoSmithKline, Sanofi, MSD, and Lilly) collectively collaborated with screeners at Weill Cornell Medicine, the Infectious Disease Research Institute (IDRI), and the National Institute of Allergy and Infectious Diseases (NIAID), pharmacologists at Rutgers University, and medicinal chemists at the University of North Carolina to screen ∼8900 β-lactams, predominantly cephalosporins, and characterize active compounds. In a striking contrast to historical expectation, 18% of β-lactams screened were active against Mtb, many without a β-lactamase inhibitor. One potent cephaloporin was active in Mtb-infected mice. The steps outlined here can serve as a blueprint for multiparty, intra- and intersector collaboration in the development of anti-infective agents.

20 March 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
FCFraser Cunningham
Fraser Cunningham
JEJorge Esquivias
Jorge Esquivias
RFRaquel Fernández-Menéndez
Raquel Fernández-Menéndez
APArancha Pérez
Arancha Pérez
AGAna Guardia
Ana Guardia
RBRobert H. Bates
Robert H. Bates

16 February 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
DNDereje Abate Negatu
Dereje Abate Negatu
RRRubén González del Río
Rubén González del Río
MCMónica Cacho-Izquierdo
Mónica Cacho-Izquierdo
DBDavid Barros-Aguirre
David Barros-Aguirre
JLJoël Lelievre
Joël Lelievre
Thomas DickThomas Dick
Thomas Dick
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection.